Briquilimab

DB18136InvestigationalProtein Based Therapies

Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).

Mechanism: Pharmacologically active on Mast/stem cell growth factor receptor Kit
Curator reviewed
Also known as: IMMUNOGLOBULIN G1 (297-GLUTAMINE), ANTI-(HUMAN C-KIT RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JSP191 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL JSP191 .KAPPA.-CHAIN, DIMER
Code names: AMG-191 · JSP-191

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Briquilimab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.